Akebia Therapeutics

306 articles with Akebia Therapeutics

• Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. ET.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2022

  1/4/2022

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on December 31, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2021

  12/1/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 21 newly-hired employees options to purchase an aggregate of 85,000 shares of Akebia's common stock on November 30, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics Announces Participation in Upcoming Investor Conferences

  11/24/2021

   Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following investor conferences.

• Akebia Therapeutics to Present at Jefferies London Healthcare Conference

  11/15/2021

  Akebia Therapeutics, Inc. today announced that John P. Butler , Chief Executive Officer, will present at the Jefferies London Healthcare Conference, which takes place November 16 – 19, 2021.

• Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

  11/4/2021

   Akebia Therapeutics®, Inc. today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate milestones.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 01, 2021

  11/1/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 11,000 shares of Akebia's common stock on October 29, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

  11/1/2021

  Akebia Therapeutics ® , Inc. today announced the appointment of Ron Frieson to its Board of Directors.

• Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Disease

  10/29/2021

  Akebia Therapeutics, Inc and its collaborator, Otsuka Pharmaceutical Co., Ltd. (Otsuka), today announced that Otsuka Pharmaceutical Netherlands B.V. has submitted an initial marketing authorization application (MAA) to the European Medicines Agency for vadadustat,

• Akebia Therapeutics to Report Third Quarter 2021 Financial Results and Highlight Recent Company Milestones

  10/26/2021

  Akebia Therapeutics, Inc. today announced plans to release its financial results for the third quarter ended September 30, 2021, on Thursday, November 4, 2021 before the opening of the financial markets.

• Akebia Announces Vadadustat Efficacy and Safety Data to be Presented at American Society of Nephrology Kidney Week 2021

  10/18/2021

  Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that vadadustat efficacy and safety data related to clinical outcomes among patients with anemia due to chronic kidney disease (CKD) will be presented at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week).

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 180,000 shares of Akebia's common stock on September 30, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2021

  9/1/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 89,000 shares of Akebia's common stock on August 31, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics Announces September 2021 Investor Conference Schedule

  9/1/2021

  Akebia Therapeutics, Inc. today announced that John P. Butler , Chief Executive Officer, and David A. Spellman , Chief Financial Officer, will participate in the following schedule of investor conferences.

• Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones

  8/5/2021

  Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate milestones.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 03, 2021

  8/3/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 95,000 shares of Akebia's common stock on July 30, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights

  7/26/2021

  Akebia Therapeutics, Inc. today announced plans to release its financial results for the second quarter ended June 30, 2021 , on Thursday, August 5, 2021 before the opening of the financial markets.

• Thinking about buying stock in Ion Geophysical, Moneygram International, Akebia Therapeutics, iBio, or Exela Technologies?

  7/16/2021

  InvestorsObserver issues critical PriceWatch Alerts for IO, MGI, AKBA, IBIO, and XELA.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2021

  7/1/2021

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 25 newly-hired employees options to purchase an aggregate of 210,000 shares of Akebia's common stock on June 30, 2021, as inducements material to each such employee's entering into employment with Akebia.

• Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

  6/4/2021

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that it has entered into an exclusive, global license agreement with Akebia Therapeutics, Inc., a leading biopharmaceutical company focused on kidney disease, for the development and commercialization of praliciguat, an oral sGC stimulator.